Nation's Largest Renal Research Network Completes 13 Phase-I Clinical Trials;
Reports Another 34 Active Trials in Late Stage Development
EL SEGUNDO, Calif., May 8 /PRNewswire/ -- DaVita Clinical Research(R)
(DCR), a Phase I-IV clinical trial research service business specializing in
renal-related drug and device research and development for FDA approval,
reports it completed 13 Phase-I clinical trials in 2007 and has another 34
active trials in late stage drug development-a company record.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO)
DCR(R), through its commitment to quality, timely and accurate clinical
trials, plays a valuable role by partnering with physicians, pharmaceutical
and biotechnology companies to develop and progress new drug therapies for
patients diagnosed with chronic kidney disease (CKD). The increase in
completed and late stage trials also serves as an indication of continued
innovation and investment for end stage renal disease (ESRD) research.
"The recent DaVita Clinical Research accomplishments can be attributed to
our continuous research quality index measurements and commitment to service
excellence," said Chris Rucker, DCR Vice President and General Manager. "These
values serve as a catalyst for our research objectives, and allow us to
participate in the advancement of renal knowledge and practice."
DCR has nearly two decades of experience in conducting Phase I-IV clinical
trials, and is the nation's largest renal research network dedicated to
providing and supporting clinical and data research. DCR provides Phase-I
renal studies services including renal, Hepatic, CV, Dermatology and Endocrine
subjects, Pharmacokinetics, Pharmacodynamics and drug interactions. Phase II-
IV renal studies services include pre ESRD and ESRD subjects, clinical
efficacy and safety, special populations and post marketing studies.
"Since departing full-time academics for private practice, DaVita Clinical
Research has helped me to continue my clinical research efforts," said Robert
I. Lynn, M.D. of Nephrology & Hypertension Associates. "The staff locates high
quality studies and makes it easier to do clinical trials in DaVita(R)
facilities. They are friendly, responsive and supportive, and DaVita Clinical
Research really does work with you not only to get a research effort 'off the
ground,' but also to help it develop and prosper."
DaVita and DaVita Clinical Research are registered trademarks of DaVita
Inc. All other trademarks are the properties of their respective owners.
About DaVita Inc.
DaVita Inc., a FORTUNE 500(R) company, is a leading provider of kidney
care in the United States, providing dialysis services and education for
patients with chronic kidney failure and end stage renal disease. DaVita
manages more than 1,300 outpatient facilities and acute units in more than 700
hospitals located in 43 states and the District of Columbia, serving
approximately 107,000 patients. For more information about DaVita and its
kidney education programs, please visit http://www.davita.com.
SOURCE DaVita Clinical Research
Basak Ertan, 1-800-310-4872, for DaVita Clinical Research
